Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local ...

Novo Nordisk is expanding discounted sales of its Wegovy weight loss drug. Novo Nordisk is also licensing a new weight loss drug from China. Crunching the data, the news looks relatively worse for ...

The Novo Nordisk Foundation’s project to explore food processing has created some controversy of late. Initially, the project was framed as ‘the next generation’ of the ‘Nova’ classification, with its ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British Pharmaceutical Industry (ABPI) has reinstated the Danish drugmaker after seeing ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance ...